Interleukin Genetics to pursue U.S. patent for PerioPredict
Interleukin Genetics, Inc. announced that it has received a notice of allowance for a patent by the United States Patent and Trademark Office (USPTO) for an application covering the Company’s PerioPredict Genetic Risk Test.
Interleukin Genetics, Inc. announced that it has received a notice of allowance for a patent by the United States Patent and Trademark Office (USPTO) for an application covering the company’s PerioPredict Genetic Risk Test. The application, titled “Method for Determining Severity and Progression of Periodontal Disease,” has allowed claims covering methods of determining a subject’s genotype to ascertain their risk of developing severe periodontal disease and the treatment of those at risk to slow the progression of the disease.
“This allowed application forms another key component of our commercial strategy for PerioPredict,” said Mark Carbeau, Interleukin Genetics' CEO. “We continue to make investments to advance the clinical utility of PerioPredict to provide caregivers useful genetic insights to manage inflammation. This allowed application supports these investments in science and evidence to ultimately provide improved care to patients.”
The patent portfolio that forms Interleukin’s intellectual property continues to strengthen, covering both current products and those under development. Over the past year, the following patents have issued in major markets throughout the world.
Improved Method and Kit for Determining Severity and Progression of Periodontal Disease (New Zealand, granted July 2015)
Genetic Markers for Weight Management and Methods of Use Thereof (China, granted August 2015; Japan, granted January 2016; and European Union, granted March 2016)
Genetic Predisposition to Osteoarthritis Associated Conditions (Australia, granted May 2015; Japan, granted June 2015; and European Union, granted November 2015)
“Our commitment to cutting edge science is evidenced by our success in obtaining key patents that support our product portfolio,” said Dr. Ken Kornman, Chief Scientific Officer of Interleukin Genetics. “Securing patent protection is a critical element of our ongoing product development strategy to support the long-term success of our commercial products. Strategically, we are committed to expand our intellectual property with additional key patent applications pending in the U.S. and globally.”
PerioPredict is a genetic test that identifies individuals with an increased risk for severe and progressive periodontitis, due to a life-long genetic predisposition to overproduce Interleukin-1 (IL-1), a key mediator of inflammation. The PerioPredict test is made available to employees in covered health plans under the supervision of a licensed dentist or physician, and the results provide important information to dental professionals for assessing prevention and treatment options for their patients. The PerioPredict test is run solely in Interleukin’s CLIA-certified lab in Waltham, MA.